THY1 and neoplasm: To test the therapeutic capacity of different antibody isotypes to control tumor growth in a syngeneic mouse model, C57BL/6 mice were subcutaneously injected with B16-OVA-Thy1.1 cells and treated with either anti-Thy1.1 IgG2a, IgG1, or IgE antibodies, starting on day 7 after tumor cells transfer (Fig. 4A).